CONFERENCE PROGRAM

Wednesday, May 8

4:00 p.m.-8:00 p.m.  REGISTRATION  
Marina Ballroom Foyer

7:00 p.m.-8:00 p.m.  WELCOME AND KEYNOTE LECTURE  
Marina Ballroom FG  
Targeting developmental pathways in cancer  
Frederic J. de Sauvage, Genentech, Inc., South San Francisco, CA

8:00 p.m.-9:30 p.m.  OPENING RECEPTION  
Marina Ballroom DE

Thursday, May 9

7:30 a.m.-8:30 a.m.  CONTINENTAL BREAKFAST  
Marina Ballroom DE

8:30 a.m.-10:30 a.m.  PLENARY SESSION 1: MECHANISMS OF HIPPO PATHWAY REGULATION IN CANCER  
Marina Ballroom FG  
Session Chair: Duojia D.J. Pan, Howard Hughes Medical Institute, Dallas, TX  
Hippo signaling in normal and cancer growth  
Duojia D.J. Pan  
The Hippo pathway in melanoma  
Kieran F. Harvey, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia  
Regulation of the Hippo pathway in cancer  
Kun-Liang Guan, UCSD Moores Cancer Center, La Jolla, CA  
Regulation of TEAD by p38 MAPK-induced cytoplasmic translocation*  
Hyun Woo Park, Yonsei University, Seoul, South Korea  
Spatial resets modulate YAP-dependent transcription*  
Matt Franklin, Stanford University, Stanford, CA

10:30 a.m.-11:00 a.m.  BREAK  
Marina Ballroom Foyer

*Short talk from proffered abstract.
11:00 a.m.-12:30 p.m.  
PLENARY SESSION 2: HIPPO PATHWAY IN RARE/PEDIATRIC CANCERS  
Marina Ballroom FG  
Session Chair: Brian P. Rubin, The Cleveland Clinic, Cleveland, OH  
Hippo pathway dysregulation in epithelioid hemangioendothelioma  
Brian P. Rubin  
Dysregulated Hippo signaling in childhood rhabdomyosarcoma  
Corinne Mary Linardic, Duke University School of Medicine, Durham, NC  
YAP/TAZ requirement in mesenchyme-originated intestinal hamartomatous polyposis*  
Junhao Mao, University of Massachusetts Medical School, Worcester, MA  
Integrin-mediated mechano-transduction controls HER2 oncogenic signaling and activation of YAP in breast cancer*  
Filippo Giancotti, The University of Texas MD Anderson Cancer Center, Houston, TX

12:30 p.m.-2:30 p.m.  
POSTER SESSION A / LUNCH  
Marina Ballroom DE

2:30 p.m.-4:30 p.m.  
PLENARY SESSION 3: HIPPO SIGNALING IN STEM CELLS AND REGENERATION AND LINKS WITH OTHER KEY SIGNALING PATHWAYS  
Marina Ballroom FG  
Session Chair: Georg Halder, VIB-KU Leuven Center for Cancer Biology, Leuven, Belgium  
Hippo signaling in liver regeneration and liver tumors  
Georg Halder  
Regulation of YAP by tyrosine phosphorylation of core Hippo pathway components: Lessons learned from the GNAQ oncogene and FAK  
J. Silvio Gutkind, UCSD Moores Cancer Center, La Jolla, CA  
The crosstalk between Hippo-YAP/TAZ and PTEN-AKT signaling in liver metabolic dysregulation and tumorigenesis  
Dae-Sik Lim, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea  
Inhibition of the Hippo pathway by AMPK-family kinases  
Liliana Attisano, University of Toronto, Toronto, ON, Canada

4:30 p.m.-5:00 p.m.  
BREAK  
Marina Ballroom Foyer

*Short talk from proffered abstract.
CONFERENCE PROGRAM

5:00 p.m.-6:30 p.m.  PLENARY SESSION 4: TRANSCRIPTIONAL REGULATION IN CANCER AND BEYOND
Marina Ballroom FG

Session Chair: Yingzi Yang, Harvard School of Dental Medicine, Boston, MA

Hippo signaling is intrinsically regulated during cell cycle progression
Yingzi Yang

Targeting autopalmitoylation of TEAD transcription factors
Xu Wu, Massachusetts General Hospital, Boston, MA

Genome-wide screening identifies novel YAP modulators*
Dana Elster, Leibniz Institute on Aging, Fritz Lipmann Institute e.V., Jena, Thüringen, Germany

Mechanistic insights for TEAD/YAP activation*
Jeffrey Holden, Genentech, South San Francisco, CA

6:30 p.m.  EVENING OFF / DINNER ON OWN

Friday, May 10

7:30 a.m.-8:30 a.m.  CONTINENTAL BREAKFAST
Marina Ballroom DE

8:30 a.m.-10:30 a.m.  PLENARY SESSION 5: REGULATORY NETWORKS, CANCER PATHWAY CROSSTALK, AND INTEGRATION OF MODEL SYSTEMS
Marina Ballroom FG

Session Chair: Nicolas Tapon, The Francis Crick Institute, London, United Kingdom

Regulation of the Hippo pathway in cancer
Fernando Camargo, Boston Children’s Hospital, Boston, MA

The roles of YAP/TAZ in tumor maintenance
Chunling Yi, Georgetown University, Washington, DC

Growth control and Hippo signaling in the Drosophila abdomen
Nicolas Tapon

Regulation of SAV1-STRIPAK antagonism by YSK1-dependent phosphorylation
Xuelian Luo, UT Southwestern Medical Center, Dallas, TX

10:30 a.m.-11:00 a.m.  BREAK
Marina Ballroom Foyer

*Short talk from proffered abstract.
11:00 a.m.-12:30 p.m.  PLENARY SESSION 6: DRUGGING THE HIPPO PATHWAY  
Marina Ballroom FG  
Session Chair: Wanjin Hong, Institute of Molecular and Cell Biology, Proteos, Singapore  
Hippo pathway deregulation in cancers  
Anwesha Dey, Genentech, Inc., South San Francisco, CA  
Targeting the Hippo pathway for candidate cancer therapy  
Wanjin Hong  
Targeting the Hippo-YAP pathway with small-molecule compounds*  
Tracy Tang, Vivace Therapeutics, San Mateo, CA  
Systematic pan-cancer analyses of Hippo pathway deregulation in cancer*  
Matthew Chang, Genentech, Inc., South San Francisco, CA

12:30 p.m.-2:30 p.m.  FREE TIME / LUNCH ON OWN

2:30 p.m.-4:30 p.m.  PLENARY SESSION 7: THERAPY AND RESISTANCE FACTORS IN CANCERS  
Marina Ballroom FG  
Session Chair: Bin Zhao, Zhejiang University, Hangzhou, China  
The role of the Hippo/YAP pathway in cancer drug resistance  
Trever G. Bivona, University of California, San Francisco, San Francisco, CA  
LATS1 and LATS2 suppress breast cancer progression by maintaining cell identity and metabolic state  
Yael Aylon, Weizmann Institute of Science, Rehovot, Israel  
The Hippo pathway in cancer  
Bin Zhao  
Roles of YAP1 in KRAS and β-catenin signaling  
William C. Hahn, Dana-Farber Cancer Institute, Boston, MA

4:30 p.m.-6:30 p.m.  POSTER SESSION B / RECEPTION  
Marina Ballroom DE

6:30 p.m.  EVENING OFF / DINNER ON OWN

*Short talk from proffered abstract.
CONFERENCE PROGRAM

Saturday, May 11

7:30 a.m.-8:30 a.m.  CONTINENTAL BREAKFAST
Marina Ballroom DE

8:30 a.m.-10:00 a.m.  PLENARY SESSION 8: HIPPO PATHWAY, INFLAMMATION, MICROENVIRONMENT, AND CANCER IMMUNITY
Marina Ballroom FG
Session Chair: Ira Tabas, Columbia University Health Sciences, New York, NY
The role of hepatocyte TAZ in NASH and NASH-HCC
Ira Tabas
YAP in cancer and inflammation
Deepavali Chakravarti, The University of Texas MD Anderson Cancer Center, Houston, TX
The Hippo pathway integrates PI3K-Akt signals with mechanical cues to control tissue growth*
Barry Thompson, Francis Crick Institute, London, United Kingdom
Hippo regulates intestinal regeneration by inducing revival stem cells*
Jeff Wrana, Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada

10:00 a.m.-10:30 a.m.  BREAK
Marina Ballroom Foyer

10:30 a.m.-12:00 p.m.  PLENARY SESSION 9: BROADER ROLES IN CANCER SIGNALING
Marina Ballroom FG
Session Chair: Helen McNeill, Washington University, St. Louis, MO
Adult deletion of LATS1/2 leads to sarcomatoid renal cell carcinoma
Helen McNeill
Oncogenic lncRNA promotes escape from intrinsic Hippo tumor suppression
Liuqing Yang, The University of Texas MD Anderson Cancer Center, Houston, TX
Regulation of Hippo and TAZ signaling in breast cancer
Kunxin Luo, University of California, Berkeley, Berkeley, CA

12:00 p.m.-12:15 p.m.  CLOSING REMARKS
Marina Ballroom FG
Fernando Camargo, Boston Children’s Hospital, Boston, MA
Anwesha Dey, Genentech, Inc., South San Francisco, CA
Kun-Liang Guan, UCSD Moores Cancer Center, La Jolla, CA

12:15 p.m.  DEPARTURE

*Short talk from proffered abstract.